Flavored E-Cigarette PMTAs in 2026: What FDA’s New Draft Guidance Actually Changes

The FDA’s Center for Tobacco Products issued a new draft guidance on March 9, 2026, that is the most detailed statement yet on how the agency will evaluate premarket applications for flavored e-cigarettes. The guidance formalizes a flavor-specific, evidence-scaled framework — and it shifts FDA’s prior position on device access restrictions in a way that companies with DAR-equipped products need to understand immediately.

The comment period closes May 11, 2026. If your company is affected and has not considered whether to submit comments, that window is almost gone.

Here is what the guidance actually changes, and what ENDS companies should do about it.

---

The Legal Backdrop: What the Supreme Court Settled

Before getting to the guidance, one development that every ENDS company needs to have on its radar: the U.S. Supreme Court has now upheld FDA’s comparative efficacy framework for evaluating flavored ENDS PMTAs. In FDA v. Wages and White Lion Investments, the Court affirmed FDA’s approach to assessing whether flavored products provide sufficient adult benefit to outweigh youth risk.

That decision closes off a significant avenue of legal challenge for companies that have been betting on judicial pushback to FDA’s evidence standards. The comparative efficacy framework is now judicially settled. Companies evaluating whether to fight FDA’s PMTA standards in court should factor that into their strategy.

---

What the March 2026 Guidance Actually Changes

The guidance does not rewrite the PMTA standard. The legal test — whether marketing the product is appropriate for the protection of the public health under section 910 of the FD&C Act (21 U.S.C. § 387j) — remains the same. What the guidance does is formalize and clarify how FDA applies that standard to different flavor categories.

The graduated risk proportionate evaluation. This is the guidance’s central contribution and the term you will encounter in every serious PMTA discussion going forward. FDA has now drawn a clearer line between flavor categories based on their association with youth use. The evidentiary burden an applicant must meet rises with the flavor’s assessed youth appeal. Fruit, candy, dessert, and other sweet flavors — which accounted for 87.6% of youth ENDS use in 2024 national surveillance data — face the highest evidentiary burden. Menthol, mint, coffee, and spice flavors face a graduated but lower threshold. Tobacco-flavored products remain the baseline.

In practical terms: a company seeking authorization for a watermelon disposable vape needs substantially more evidence of adult benefit than a company seeking authorization for a menthol pod. The guidance makes that differential explicit in a way prior FDA communications did not.

The shift on device access restrictions. This is the change most likely to catch ENDS companies off guard, and it matters if your PMTA strategy has relied on DAR technology to address FDA’s youth concerns.

FDA had previously suggested — including in a 2024 technical project lead review of NJOY products — that device access restrictions, such as biometric unlocking, age-gating, and geofencing, could meaningfully mitigate youth risk for flavored ENDS and potentially reduce the showing of adult benefit required. The March 2026 guidance pulls back from that position. FDA now states clearly that for candy, dessert, and other sweet-flavored ENDS, DAR technology “without adequate and substantial evidence demonstrating sufficient mitigation of youth risk” is insufficient to overcome the heightened concerns associated with those flavor categories.

DARs are not irrelevant — the guidance preserves FDA’s interest in them as part of the overall assessment. But they are no longer positioned as a potential path around the adult-benefit requirement for high-youth-appeal flavors. If your PMTA strategy assumed that strong DAR implementation would reduce the evidence burden for a fruit or candy flavor, that strategy needs to be reassessed in light of the guidance.

---

PMTA Authorization Is Still Required — and Enforcement Remains Active

A Premarket Tobacco Product Application is required for new tobacco products that do not fall within another lawful pathway. ENDS products that are new tobacco products cannot legally be marketed in the United States without FDA authorization. That includes most e-liquids, disposable vapes, cartridges, and pods.

FDA has repeatedly stated that unauthorized tobacco products are subject to enforcement. The risk includes Warning Letters, civil money penalties, import detention, injunction, and seizure. Enforcement has not slowed: FDA has continued to update import alerts to reinforce that all unauthorized e-cigarettes may be detained without physical examination.

A company’s current marketing status matters. Continuing to sell unauthorized flavored ENDS products creates enforcement risk while a PMTA is pending or before a PMTA is filed. Companies should evaluate current inventory, distribution, imports, online sales, and retailer relationships with their current authorization status in mind.

---

What Makes Flavored ENDS Applications So Difficult

For any flavored ENDS product other than tobacco and, in limited circumstances, menthol, FDA’s primary concern is whether the applicant can show, with robust and reliable evidence, that the flavored product offers an added public health benefit relative to a tobacco-flavored ENDS — specifically, in facilitating adult combustible cigarette smokers to completely switch or significantly reduce their use.

General statements about harm reduction, consumer preference surveys, and market-share data are not enough. FDA expects product-specific evidence. That expectation is not new, but the graduated framework makes the required quantum of evidence more transparent — and higher for higher-youth-appeal flavors.

The guidance also reinforces that FDA takes a holistic approach to the APPH assessment, looking beyond youth initiation rates and adult switching to product-specific risks such as exposure to harmful and potentially harmful constituents, abuse liability, and the totality of marketing and distribution controls.

---

What Companies Should Evaluate Before Filing or Updating a PMTA

What flavor category is the product in? FDA’s risk analysis differs significantly depending on whether the flavor is tobacco, menthol, mint, fruit, candy, dessert, or another non-tobacco category. The more youth-appealing the flavor profile, the higher the evidentiary burden. Applicants should map their product’s flavor against the guidance’s framework before designing or commissioning studies.

What is the product-specific adult benefit? The applicant must be able to explain why this specific product provides an added benefit to adult smokers compared to other available products — including tobacco-flavored ENDS. General harm-reduction arguments are not sufficient. The evidence should be tailored to the specific flavor and product type.

What evidence supports adult switching or reduced harm? FDA will look for reliable, well-designed studies supporting the argument that the product benefits adult smokers. Companies should assess whether their existing studies are strong enough, appropriately designed, and relevant to the specific product at issue.

What evidence addresses youth risk? Applicants need evidence-based responses to concerns about youth initiation, youth appeal, product design, flavor descriptors, packaging, advertising channels, social media, influencer content, and retail controls. DAR technology should be included where available, but — as the guidance now makes clear — should not be presented as a substitute for adult-benefit evidence for high-youth-appeal flavor categories.

Is the company currently selling unauthorized products? Companies should be clear-eyed about this. Selling unauthorized products while pursuing a PMTA creates compounding enforcement exposure if the PMTA is denied or delayed.

---

Should You Submit Comments on the Draft Guidance?

Because the guidance is draft, stakeholders can submit comments to FDA through the public docket (FDA-2026-D-1817) by May 11, 2026. That deadline is today or imminent depending on when you are reading this — if it has not passed, the window for submitting comments is essentially closed.

For companies that did engage in the comment process, or for those evaluating the final guidance when it is issued, the most useful comments on draft guidance of this kind typically address areas where FDA’s proposed approach is unclear, legally unsupported, scientifically contested, or practically unworkable — supported by data. Comments that simply argue flavored products are important to adult smokers, without more, are unlikely to carry weight.

---

Practical Takeaway

FDA’s March 2026 draft guidance gives the flavored ENDS industry clearer rules of engagement, but it does not lower the bar. The Supreme Court has now settled the legal framework FDA uses. FDA has formalized a graduated, flavor-specific evidence requirement that makes the highest-youth-appeal flavor categories harder to authorize, not easier. And the prior assumption that robust device access restrictions could substitute for adult-benefit evidence no longer holds for candy, dessert, and sweet-flavored products.

For companies in the flavored ENDS space, this is not the time for a casual regulatory strategy. PMTA planning, marketing review, import compliance, and enforcement-risk assessment should be handled with current FDA expectations and Wages in mind.

Need help evaluating a flavored ENDS PMTA, reviewing your current enforcement exposure, or responding to an FDA Warning Letter? Contact FDA Atty to discuss your options. You can also learn more about our tobacco and e-cigarette regulatory services.

---

Frequently Asked Questions

What is a PMTA and do I need one to sell flavored vapes? A Premarket Tobacco Product Application is the authorization pathway required for most new tobacco products, including the majority of e-cigarettes, vapes, disposables, and e-liquids sold in the U.S. market. Products that were commercially marketed before February 15, 2007 are pre-existing tobacco products that do not require a PMTA. Almost all flavored ENDS products currently on the market are new tobacco products and cannot be legally sold without FDA authorization, which in most cases requires a PMTA. Products sold without authorization are subject to FDA enforcement including Warning Letters, import holds, seizure, and civil money penalties.

What did FDA’s March 2026 draft guidance change about flavored e-cigarette applications? Two things changed materially. First, the guidance formalized a “graduated risk proportionate evaluation” that explicitly ties the required quantum of adult-benefit evidence to a flavor’s assessed youth appeal — fruit, candy, and sweet flavors face the highest burden; menthol and mint face a graduated but lower threshold; tobacco flavor is the baseline. Second, the guidance shifted FDA’s prior position on device access restrictions (DARs): FDA now states that for candy, dessert, and sweet-flavored ENDS, DAR technology alone is insufficient to overcome heightened youth-risk concerns without adequate evidence of mitigation. Companies that had been counting on DAR implementation to reduce the adult-benefit evidence requirement for high-appeal flavors need to reassess their strategy.

What flavors are most likely to receive FDA authorization in a PMTA? FDA has only authorized ENDS products in tobacco and menthol flavors to date, and all current authorizations have gone to large tobacco manufacturers. The graduated framework in the March 2026 guidance suggests that menthol, mint, coffee, and spice flavors face a lower evidentiary threshold than fruit, candy, and sweet flavors — though “lower” does not mean “easy.” No non-tobacco, non-menthol flavored ENDS product has received FDA authorization as of the date of this post.

Can marketing restrictions or device access restrictions satisfy FDA’s youth-risk requirements? Partially. Marketing restrictions — age gates, adult-only channels, retailer controls, social media controls — are important components of a PMTA and should be included. But FDA has consistently stated that marketing restrictions alone cannot sufficiently mitigate youth risk for flavored ENDS. Device access restrictions (DARs) such as biometric unlocking and geofencing carry more weight, but the March 2026 guidance makes clear that for candy, dessert, and sweet-flavored products, even robust DAR implementation is not sufficient without product-specific evidence of adequate youth-risk mitigation and adult benefit.

Is FDA still enforcing against unauthorized flavored ENDS products? Yes, actively. FDA has continued updating import alerts to authorize detention without physical examination of unauthorized e-cigarettes, and it has pursued Warning Letters, civil money penalties, injunctions, and seizures against unauthorized ENDS products. The existence of a pending PMTA does not automatically authorize continued marketing. Companies selling unauthorized products while a PMTA is pending or under review remain subject to enforcement action.

---

This post is intended for general informational purposes and does not constitute legal advice. PMTA strategy, enforcement risk, and regulatory compliance are fact-specific. Contact an FDA regulatory attorney for advice specific to your situation.